Company / SG&A Expense
Corbus Pharmaceuticals Holdings, Inc. SG&A Expense History
FY2015-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$20.4M
FY2022
5-year range
$9.0M / $28.5M
FY2018-FY2022
Trend
-28.3%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $24M to $20M over the past 2 years.
Based on SEC 10-K filings.
$20M in FY2022 with a 5-year CAGR of +41.4%.
Improved from $24M to $20M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +16.4%
- 5-Year CAGR
- +41.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +41.4%, indicating consistent growth.
- In FY2022, sg&a expense decreased 28.3% year-over-year.
- Peak sg&a expense was recorded in FY2021.
- Lowest sg&a expense in the period was in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -12.48 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | $20.4M | -28.3% |
| FY2021 | $28.5M | +20.5% |
| FY2020 | $23.6M | +82.5% |
| FY2019 | $13.0M | +44.5% |
| FY2018 | $9.0M | +148.1% |
| FY2017 | $3.6M | +0.0% |
| FY2016 | $3.6M | +159.7% |
| FY2015 | $1.4M | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026